Asia Pacific Clinical Trials Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Historic Data: 2021-2022   |   Base Year: 2023   |   Forecast Period: 2024-2031

Report Coverage:
  • Study Design (Interventional Trials, Expanded Access Trials)
  • Indications (Autoimmune/Inflammation, Pain Management, Oncology, Neurological Disorders, Diabetes, Obesity, Metabolic Disorders, Cardiovascular, Others)
  • Phase Type (Phase I, Phase II, Phase III)

No. of Pages: 129
Report Code: BMIRE00028988
Category: Life Sciences
Asia Pacific Clinical Trials Market
Free Sample Buy Now

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Data Triangulation and Validation

4. Asia Pacific Clinical Trials Market Landscape

4.1 Overview
4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Asia Pacific Clinical Trials Market – Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints

6. Asia Pacific Clinical Trials Market Regional Analysis

6.2 Asia Pacific Clinical Trials Market Revenue 2021-2031 (US$ Million)
6.3 Asia Pacific Clinical Trials Market Forecast Analysis

7. Asia Pacific Clinical Trials Market Analysis – by Study Design

7.1 Interventional Trials
  • 7.1.1 Overview
  • 7.1.2 Interventional Trials: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Expanded Access Trials
  • 7.2.1 Overview
  • 7.2.2 Expanded Access Trials: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Clinical Trials Market Analysis – by Indications

8.1 Autoimmune/Inflammation
  • 8.1.1 Overview
  • 8.1.2 Autoimmune/Inflammation: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Pain Management
  • 8.2.1 Overview
  • 8.2.2 Pain Management: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Oncology
  • 8.3.1 Overview
  • 8.3.2 Oncology: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Neurological Disorders
  • 8.4.1 Overview
  • 8.4.2 Neurological Disorders: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Diabetes
  • 8.5.1 Overview
  • 8.5.2 Diabetes: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Obesity
  • 8.6.1 Overview
  • 8.6.2 Obesity: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.7 Metabolic Disorders
  • 8.7.1 Overview
  • 8.7.2 Metabolic Disorders: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.8 Cardiovascular
  • 8.8.1 Overview
  • 8.8.2 Cardiovascular: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.9 Others
  • 8.9.1 Overview
  • 8.9.2 Others: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Clinical Trials Market Analysis – by Phase Type

9.1 Phase I
  • 9.1.1 Overview
  • 9.1.2 Phase I: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Phase II
  • 9.2.1 Overview
  • 9.2.2 Phase II: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Phase III
  • 9.3.1 Overview
  • 9.3.2 Phase III: Asia Pacific Clinical Trials Market – Revenue and Forecast, 2021-2031 (US$ Million)

10. Asia Pacific Clinical Trials Market – Asia Pacific Analysis

10.1 Overview

10.2 Asia Pacific
  • 10.2.1 Asia Pacific Clinical Trials Market Breakdown, by Key Country, 2024 and 2031 (%)
  • 10.2.1.1 Asia Pacific Clinical Trials Market – Revenue and Forecast Analysis – by Country
  • 10.2.1.1 China: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.2.1.1.1 China: Asia Pacific Clinical Trials Market Breakdown, by Study Design
    • 10.2.1.1.2 China: Asia Pacific Clinical Trials Market Breakdown, by Indications
    • 10.2.1.1.3 China: Asia Pacific Clinical Trials Market Breakdown, by Phase Type
  • 10.2.1.2 Japan: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.2.1.2.1 Japan: Asia Pacific Clinical Trials Market Breakdown, by Study Design
    • 10.2.1.2.2 Japan: Asia Pacific Clinical Trials Market Breakdown, by Indications
    • 10.2.1.2.3 Japan: Asia Pacific Clinical Trials Market Breakdown, by Phase Type
  • 10.2.1.3 India: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.2.1.3.1 India: Asia Pacific Clinical Trials Market Breakdown, by Study Design
    • 10.2.1.3.2 India: Asia Pacific Clinical Trials Market Breakdown, by Indications
    • 10.2.1.3.3 India: Asia Pacific Clinical Trials Market Breakdown, by Phase Type
  • 10.2.1.4 Australia: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.2.1.4.1 Australia: Asia Pacific Clinical Trials Market Breakdown, by Study Design
    • 10.2.1.4.2 Australia: Asia Pacific Clinical Trials Market Breakdown, by Indications
    • 10.2.1.4.3 Australia: Asia Pacific Clinical Trials Market Breakdown, by Phase Type
  • 10.2.1.5 South Korea: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.2.1.5.1 South Korea: Asia Pacific Clinical Trials Market Breakdown, by Study Design
    • 10.2.1.5.2 South Korea: Asia Pacific Clinical Trials Market Breakdown, by Indications
    • 10.2.1.5.3 South Korea: Asia Pacific Clinical Trials Market Breakdown, by Phase Type
  • 10.2.1.6 Indonesia: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.2.1.6.1 Indonesia: Asia Pacific Clinical Trials Market Breakdown, by Study Design
    • 10.2.1.6.2 Indonesia: Asia Pacific Clinical Trials Market Breakdown, by Indications
    • 10.2.1.6.3 Indonesia: Asia Pacific Clinical Trials Market Breakdown, by Phase Type
  • 10.2.1.7 Malaysia: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.2.1.7.1 Malaysia: Asia Pacific Clinical Trials Market Breakdown, by Study Design
    • 10.2.1.7.2 Malaysia: Asia Pacific Clinical Trials Market Breakdown, by Indications
    • 10.2.1.7.3 Malaysia: Asia Pacific Clinical Trials Market Breakdown, by Phase Type
  • 10.2.1.8 Singapore: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.2.1.8.1 Singapore: Asia Pacific Clinical Trials Market Breakdown, by Study Design
    • 10.2.1.8.2 Singapore: Asia Pacific Clinical Trials Market Breakdown, by Indications
    • 10.2.1.8.3 Singapore: Asia Pacific Clinical Trials Market Breakdown, by Phase Type
  • 10.2.1.9 Rest of Asia Pacific: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2031 (US$ Million)
    • 10.2.1.9.1 Rest of Asia Pacific: Asia Pacific Clinical Trials Market Breakdown, by Study Design
    • 10.2.1.9.2 Rest of Asia Pacific: Asia Pacific Clinical Trials Market Breakdown, by Indications
    • 10.2.1.9.3 Rest of Asia Pacific: Asia Pacific Clinical Trials Market Breakdown, by Phase Type

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments

13. Company Profiles

13.1 QVIA Holdings Inc
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Parexel International Corp
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 IXICO Plc
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Charles River Laboratories International Inc
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 ICON Plc
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 WuXi AppTec Co Ltd
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 SGS SA
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Syneos Health Inc
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Thermo Fisher Scientific Inc
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Laboratory Corp of America Holdings
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments
13.11 CliniRx Research Private Limited
  • 13.11.1 Key Facts
  • 13.11.2 Business Description
  • 13.11.3 Products and Services
  • 13.11.4 Financial Overview
  • 13.11.5 SWOT Analysis
  • 13.11.6 Key Developments
13.12 Caidya
  • 13.12.1 Key Facts
  • 13.12.2 Business Description
  • 13.12.3 Products and Services
  • 13.12.4 Financial Overview
  • 13.12.5 SWOT Analysis
  • 13.12.6 Key Developments
13.13 Oracle Corp
  • 13.13.1 Key Facts
  • 13.13.2 Business Description
  • 13.13.3 Products and Services
  • 13.13.4 Financial Overview
  • 13.13.5 SWOT Analysis
  • 13.13.6 Key Developments
13.14 Medpace Holdings Inc
  • 13.14.1 Key Facts
  • 13.14.2 Business Description
  • 13.14.3 Products and Services
  • 13.14.4 Financial Overview
  • 13.14.5 SWOT Analysis
  • 13.14.6 Key Developments
13.15 SIRO Clinpharm Pvt Ltd
  • 13.15.1 Key Facts
  • 13.15.2 Business Description
  • 13.15.3 Products and Services
  • 13.15.4 Financial Overview
  • 13.15.5 SWOT Analysis
  • 13.15.6 Key Developments
13.16 QVIA Holdings Inc
  • 13.16.1 Key Facts
  • 13.16.2 Business Description
  • 13.16.3 Products and Services
  • 13.16.4 Financial Overview
  • 13.16.5 SWOT Analysis
  • 13.16.6 Key Developments

14. Appendix

14.1 About Business Market Insights
14.2 List of Abbreviations

The List of Companies - Asia Pacific Clinical Trials Market

  • QVIA Holdings Inc
  • Parexel International Corp
  • IXICO Plc
  • Charles River Laboratories International Inc
  • ICON Plc
  • WuXi AppTec Co Ltd
  • SGS SA
  • Syneos Health Inc
  • Thermo Fisher Scientific Inc
  • Laboratory Corp of America Holdings
  • CliniRx Research Private Limited
  • Caidya
  • Oracle Corp
  • Medpace Holdings Inc
  • SIRO Clinpharm Pvt Ltd
  • QVIA Holdings Inc

    • Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now
    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)